Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285426 | 1.00 | TSHR (0.45) | TSHRALDH1A1TP53MAPTPTGS1 | |
| SCHEMBL15908131 | 1.00 | TSHR (0.45) | TSHRALDH1A1TP53MAPTPTGS1 | |
| SCHEMBL18832123 | 1.00 | TSHR (0.45) | TSHRALDH1A1TP53MAPTPTGS1 | |
| SCHEMBL1924478 | 1.00 | TSHR (0.45) | TSHRALDH1A1TP53MAPTPTGS1 | |
| SCHEMBL1085851 | 0.79 | — | — | |
| SCHEMBL503261 | 0.79 | — | — | |
| SCHEMBL1576713 | 0.79 | — | — | |
| SCHEMBL1300583 | 0.79 | ALDH1A1 (0.41) | TSHRALDH1A1TET2 | |
| SCHEMBL11396749 | 0.79 | ALDH1A1 (0.41) | TSHRALDH1A1MAPTPTGS1CYP2D6 | |
| SCHEMBL3138263 | 0.77 | ALDH1A1 (0.33) | TSHRALDH1A1TP53MAPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724307-B1 | LAUNDRY SURFACTANTS HAVING INHERENT BUILDING CAPACITY DERIVED FROM BIO-BASED HYDROYACIDS AND EPOXIDES; AND PROCESS THEREFORE | BATTELLE MEMORIAL INSTITUTE (US) | 2025-07-16 | — | — | EP | claimed |
| EP-2734509-B1 | METHODS FOR PREPARATION OF AMMONIUM SALTS OF C4 DIACIDS BY FERMENTATION AND INTEGRATED METHODS FOR MAKING C4 DERIVATIVES THEREOF | ARCHER DANIELS MIDLAND CO (US) | 2018-12-26 | — | — | EP | claimed |
| CN-107001535-A | Copolymers and their use for reducing paraffin crystal crystallisation in fuels | 巴斯夫欧洲公司 | 2017-08-01 | — | — | CN | claimed |
| CN-106667962-A | Charge conversion type nanometer drug carrier and preparation method thereof | 深圳大学 | 2017-05-17 | — | — | CN | claimed |
| CN-104224721-B | Sensitively responsive polymer nano-particles, and preparation method and application thereof | 深圳先进技术研究院 | 2017-05-03 | — | — | CN | claimed |
| WO-2011119637-A9 | PREDICTING HUMAN DEVELOPMENTAL TOXICITY OF PHARMACEUTICALS USING HUMAN STEM-LIKE CELLS AND METABOLOMICS | STEMINA BIOMARKER DISCOVERY, INC. (US) | 2015-12-10 | — | — | WO | claimed |
| US-20140343039-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | ROBIN JEAN-PIERRE (CH) | 2014-11-20 | — | — | US | claimed |
| EP-2550365-A1 | PREDICTING HUMAN DEVELOPMENTAL TOXICITY OF PHARMACEUTICALS USING HUMAN STEM-LIKE CELLS AND METABOLOMICS | Stemina Biomarker Discovery, Inc. (US) | 2013-01-30 | — | — | EP | claimed |
| CN-102573845-A | Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof | SHIRE LLC | 2012-07-11 | — | — | CN | claimed |
| EP-2413937-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-02-08 | — | — | EP | claimed |
| US-20020010154-A1 | Compositions comprising cyclodextrin | THE PROCTER & GAMBLE COMPANY | 2002-01-24 | — | — | US | claimed |
| WO-2001088076-A1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | THE PROCTER & GAMBLE COMPANY (US) | 2001-11-22 | — | — | WO | claimed |
| US-6289286-B1 | Surface regeneration of biosensors and characterization of biomolecules associated therewith | BIACORE AB (SE) | 2001-09-11 | — | — | US | claimed |
| WO-2001060961-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2001-08-23 | — | — | WO | claimed |
| EP-1082607-A1 | SURFACE REGENERATION OF BIOSENSORS | Biacore AB (SE) | 2001-03-14 | — | — | EP | claimed |
| EP-0983224-A1 | PROCESS FOR PREPARING AND PURIFYING COMPLEX ESTERS | Neste Chemicals Oy (FI) | 2000-03-08 | — | — | EP | claimed |
| WO-1999063333-A1 | SURFACE REGENERATION OF BIOSENSORS | BIACORE AB (SE) | 1999-12-09 | — | — | WO | claimed |
| WO-1998050338-A1 | PROCESS FOR PREPARING AND PURIFYING COMPLEX ESTERS | NESTE CHEMICALS OY (FI) | 1998-11-12 | — | — | WO | claimed |
| US-4361471-A | Electrolytic swimming pool chlorination | WALKER & BRUNSON INCORPORATED, A CORP. OF HOUSTON, TX. | 1982-11-30 | — | — | US | claimed |
| US-4285841-A | Highly concentrated fatty acid containing liquid detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1981-08-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010154-A1 | Compositions comprising cyclodextrin | FFAR4, FRG1, FGB | TSHR 3607/4885ALDH1A1 3053/4885TP53 655/4885 |
| US-20140343039-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | CFH, C5, CHRM1 | TSHR 1045/4885ALDH1A1 1057/4885TP53 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.